BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9641002)

  • 1. Low-dose venlafaxine treatment in panic disorder.
    Papp LA; Sinha SS; Martinez JM; Coplan JD; Amchin J; Gorman JM
    Psychopharmacol Bull; 1998; 34(2):207-9. PubMed ID: 9641002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder.
    Pollack MH; Lepola U; Koponen H; Simon NM; Worthington JJ; Emilien G; Tzanis E; Salinas E; Whitaker T; Gao B
    Depress Anxiety; 2007; 24(1):1-14. PubMed ID: 16894619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study.
    Pollack MH; Worthington JJ; Otto MW; Maki KM; Smoller JW; Manfro GG; Rudolph R; Rosenbaum JF
    Psychopharmacol Bull; 1996; 32(4):667-70. PubMed ID: 8993089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot open-label study of nefazodone in panic disorder.
    Bystritsky A; Rosen R; Suri R; Vapnik T
    Depress Anxiety; 1999; 10(3):137-9. PubMed ID: 10604088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-label trial of venlafaxine in adults with attention deficit disorder.
    Adler LA; Resnick S; Kunz M; Devinsky O
    Psychopharmacol Bull; 1995; 31(4):785-8. PubMed ID: 8851654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial.
    Findling RL; Schwartz MA; Flannery DJ; Manos MJ
    J Clin Psychiatry; 1996 May; 57(5):184-9. PubMed ID: 8626348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study.
    Davidson J; Rothbaum BO; Tucker P; Asnis G; Benattia I; Musgnung JJ
    J Clin Psychopharmacol; 2006 Jun; 26(3):259-67. PubMed ID: 16702890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study.
    Amsterdam JD; Shults J
    J Clin Psychopharmacol; 2008 Apr; 28(2):171-81. PubMed ID: 18344727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venlafaxine XR in the treatment of anxiety.
    Hackett D
    Acta Psychiatr Scand Suppl; 2000; (406):30-5. PubMed ID: 11131468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine.
    Allgulander C; Mangano R; Zhang J; Dahl AA; Lepola U; Sjödin I; Emilien G;
    Hum Psychopharmacol; 2004 Aug; 19(6):387-96. PubMed ID: 15303242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder.
    Hedges D; Reimherr FW; Rogers A; Strong R; Wender PH
    Psychopharmacol Bull; 1995; 31(4):779-83. PubMed ID: 8851653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder.
    March JS; Entusah AR; Rynn M; Albano AM; Tourian KA
    Biol Psychiatry; 2007 Nov; 62(10):1149-54. PubMed ID: 17553467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venlafaxine in the treatment of children and adolescents with major depression.
    Mandoki MW; Tapia MR; Tapia MA; Sumner GS; Parker JL
    Psychopharmacol Bull; 1997; 33(1):149-54. PubMed ID: 9133767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
    Bose A; Korotzer A; Gommoll C; Li D
    Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical effect and tolerance of paxil (paroxetine) in management of panic disorders].
    Mosolov SN; Smulevich AB; Nuller IuL; Grigor'evskikh VS; Kostiukova EG; Kuzavkova MV; Koliutskaia EV; Andriushchenko AV; Zelenina EV; Kosinskiĭ VP; Kozlovskiĭ VL; Bykov SI; Pererva IG
    Ter Arkh; 2000; 72(10):16-23. PubMed ID: 11220870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venlafaxine in social phobia.
    Kelsey JE
    Psychopharmacol Bull; 1995; 31(4):767-71. PubMed ID: 8851651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder.
    Simon JS; Aguiar LM; Kunz NR; Lei D
    J Psychiatr Res; 2004; 38(3):249-57. PubMed ID: 15003430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Open-longitudinal study of the effect of dissociative symptoms on the response of patients with panic disorder to venlafaxine.
    Ural C; Belli H; Tabo A; Akbudak M
    Compr Psychiatry; 2015 Feb; 57():112-6. PubMed ID: 25492225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A controlled trial of venlafaxine in trichotillomania: interim phase I results.
    Ninan PT; Knight B; Kirk L; Rothbaum BO; Kelsey J; Nemeroff CB
    Psychopharmacol Bull; 1998; 34(2):221-4. PubMed ID: 9641004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.